Finance

Lists
Why is BVNRY up 2,61%?
Dive Deeper
BVNRY:OTCMKTS
Bavarian Nordic A/S - ADR
11,78 US$
+2,61%
(+0,30) 1D
9 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BVNRY...
Open
11,74 US$
High
11,80 US$
Low
11,72 US$
Mkt. cap
2,82 მლრდ.
Avg. vol.
2,78 ათ.
Volume
10,16 ათ.
P/E ratio
12,66
52-wk high
13,00 US$
52-wk low
8,67 US$
EPS
0,93 US$
Beta
1,45
Shares outstanding
237,82 მლნ.
No. of employees
2 ათ.
Open
11,74 US$
High
11,80 US$
Low
11,72 US$
Mkt. cap
2,82 მლრდ.
Avg. vol.
2,78 ათ.
Volume
10,16 ათ.
P/E ratio
12,66
52-wk high
13,00 US$
52-wk low
8,67 US$
EPS
0,93 US$
Beta
1,45
Shares outstanding
237,82 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development. In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S - ADR
CEOპოლ ჩაპლინი
Employees1,91 ათ.
Founded1 ივლ. 1992
Headquarters-
Sector-
Websitebavarian-nordic.com
Previous reportsAll values in DKK
Loading Previous Earnings...
Revenue
Net income
All values in DKK
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
1,79 მლრდ.
1,45 მლრდ.
1,06 მლრდ.
2,03 მლრდ.
Cost of goods sold
901,84 მლნ.
866,52 მლნ.
583,64 მლნ.
803,15 მლნ.
Cost of revenue
901,84 მლნ.
866,52 მლნ.
583,64 მლნ.
803,15 მლნ.
Research and development expenses
133,20 მლნ.
181,74 მლნ.
175,14 მლნ.
163,43 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
415,41 მლნ.
352,14 მლნ.
306,07 მლნ.
319,05 მლნ.
Operating expense
548,52 მლნ.
533,88 მლნ.
481,21 მლნ.
482,48 მლნ.
Total operating expenses
1,45 მლრდ.
1,40 მლრდ.
1,06 მლრდ.
1,29 მლრდ.
Operating income
344,56 მლნ.
50,55 მლნ.
-7,01 მლნ.
748,77 მლნ.
Other non operating income
-1,75 მლნ.
-1,74 მლნ.
-1,71 მლნ.
-1,74 მლნ.
EBT including unusual items
1,17 მლრდ.
28,19 მლნ.
23,32 მლნ.
759,63 მლნ.
EBT excluding unusual items
361,71 მლნ.
62,45 მლნ.
23,72 მლნ.
760,01 მლნ.
Income tax expense
77,02 მლნ.
326,99 მლნ.
6,36 მლნ.
27,99 მლნ.
Effective tax rate
6,58%
1 159,86%
27,30%
3,68%
Other operating expenses
-88,00 ათ.
-
-
-
Net income
1,09 მლრდ.
-298,80 მლნ.
16,95 მლნ.
731,64 მლნ.
Net profit margin
60,89%
-20,59%
1,60%
35,96%
Earnings per share
-
-3,30
-
8,90
Interest and investment income
12,90 მლნ.
19,84 მლნ.
14,86 მლნ.
13,06 მლნ.
Interest expense
-1,37 მლნ.
-2,18 მლნ.
-1,41 მლნ.
-3,56 მლნ.
Net interest expenses
11,53 მლნ.
17,66 მლნ.
13,45 მლნ.
9,50 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
515,50 მლნ.
166,77 მლნ.
165,45 მლნ.
924,55 მლნ.
Gain or loss from assets sale
-
18,43 მლნ.
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები